Riskpilot← Back to searchSign inGet full accessHestiaMedtech AB
ABActiveOrg 5569244907Råövägen 309Research and experimental development on natural sciences and engineering · NACE 7210Est. 20130 employees
Revenue 2025
SEK 0
EBITDA margin
—
Equity ratio
81.5%
Financial strength
Net profit 2025
SEK -1K
-1489% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -2K | — |
| Net profit | SEK -1K | -1489% |
| Total assets | SEK 32K | -4% |
| Equity | SEK 26K | -5% |
| Employees | 0 | — |
Legal name
HestiaMedtech AB
Org number
5569244907
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1 mars 2013
Share capital
SEK 55 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska bedriva utveckling och försäljning av produkter inom medicinteknisk industri och därmed förenlig verksamhet.
Address
Råövägen 309
Email
fritiof.ponten@biotechfluidics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 7 | 7 | −3 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | 0 | −1 | — | −2 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 0 | 0 | −1 | 0 | −2 |
| Net financials | — | — | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | −1 | 0 | −1 |
| Tax | −0 | — | — | — | — |
| Net profit | 0 | 0 | −1 | 0 | −1 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 32 | 38 | 33 | 34 | 32 |
| Equity | 29 | 29 | 28 | 28 | 26 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 4 | 9 | 5 | 6 | 6 |
| Total debt | 4 | 9 | 5 | 6 | 6 |
EBITDA margin
-156000.0%
This company
15.8%
Market median
-987442% vs market
20212025
Equity ratio
81.5%
This company
38.2%
Market median
+113% vs market
20212025
Return on equity
-5.6%
This company
18.4%
Market median
-130% vs market
20212025
Net profit margin
-147200.0%
This company
8.1%
Market median
-1817384% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JF Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (1) | ||
BE | Audit | 2020 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2026 | |
| Former (4) | ||
| Chairman | 2020 – 2024 | |
| Board of Directors | 2024 – 2026 | |
| Deputy Board Member | 2020 – 2022 | |
| Board of Directors | 2020 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of HestiaMedtech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Björn Erik Lennart Ellison | Audit | 0 companies |
| John Fritiof Pontén | Chief Executive Officer | 0 companies |
| Leif Ted Ternander | Chairman | 0 companies |
| Annika Maria Wiman | Board of Directors | 0 companies |
| Per Magnus Nilsson | Deputy Board Member | 0 companies |
| Ulf Ingemar Kristian Johansson | Board of Directors | 0 companies |
| Lars Anders Grahn | Board of Directors | 0 companies |